An international research team, coordinated by academics from the University of Bologna and the IRCCS—Policlinico Sant'Orsola Hospital, has identified a key growth factor capable of exerting a proliferative and regenerative effect on cardiac muscle cells. The research, published in the journal *Cell Reports*, paves the way for potential new therapies to regenerate damaged hearts.

Cardiac injuries, such as those caused by myocardial infarction, infection or certain cancer therapies, result in a substantial loss of cardiac muscle cells, which are replaced by fibrotic scar tissue. Due to the extremely limited regenerative capacity of the heart, this condition often leads to heart failure.

However, we know that mammals, up to the moment of birth, are able to regenerate the heart, even following severe damage. It is only in the neonatal period that the cardiac muscle cells, cardiomyocytes, specialize to adapt to life outside the womb, permanently losing their ability to regenerate.

In order to find a strategy that could allow cardiac muscle cells to regain this regenerative ability, the researchers sought to identify growth factors whose production is reduced or switched off in the immediate postnatal period.

"We hypothesized that the loss of regenerative capacity in the early postnatal period is at least in part a consequence of reduced production
of growth factors," explains Gabriele Matteo D'Uva, professor at the Department of Medical and Surgical Sciences at the University of Bologna who coordinated the study.

"In preclinical mammalian models, we observed that expression levels of various cardiac growth factors decline rapidly after birth, in parallel with the loss of the regenerative capacity of cardiomyocytes."

Based on this observation and following a series of studies on neonatal cardiomyocytes, the researchers then discovered that some of these growth factors are able to promote cardiomyocyte proliferation.

"In particular, BMP7, a member of the family of bone morphogenetic proteins (BMPs), showed the most significant effects in promoting the proliferation of cardiac muscle cells at the neonatal stage," adds Chiara Bongiovanni, Ph.D. student in Surgical Sciences and Innovative Technologies at the University of Bologna and first author of the study.

Further confirmation also comes from zebrafish: an animal model with a spontaneous ability to regenerate the heart after injury. Again, inhibition of BMP7 reduced cardiomyocyte regeneration following cardiac injury, whereas its induction accelerated the regeneration process.

The study then investigated whether the administration of BMP7 in preclinical mammalian models (mice) could also induce cardiomyocyte proliferation even in later stages of life, when cardiomyocytes are more refractory to cell cycle re-entry and proliferation.

"The tests showed that treatment with BMP7 is able to stimulate cardiomyocyte proliferation even in the adult phase, and even more effectively after myocardial infarction," adds D'Uva.

"These results suggest that the administration of this factor could
represent a new therapeutic strategy to promote cardiac regeneration: if validated in humans, it could have a significant impact on the treatment of heart disease, one of the major cause of morbidity and mortality worldwide."

The research team behind the study is now focusing on testing synergistic combinations with other stimuli to develop even more effective strategies for tissue and organ regeneration.


Provided by University of Bologna